KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Non Operating Income (2016 - 2025)

Sarepta Therapeutics (SRPT) has 14 years of Non Operating Income data on record, last reported at $10.1 million in Q4 2024.

  • For Q4 2024, Non Operating Income fell 96.66% year-over-year to $10.1 million; the TTM value through Dec 2024 reached $42.7 million, down 86.59%, while the annual FY2024 figure was $42.7 million, 29.16% up from the prior year.
  • Non Operating Income reached $10.1 million in Q4 2024 per SRPT's latest filing, down from $11.8 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $301.1 million in Q4 2023 and bottomed at -$118.1 million in Q4 2021.
  • Average Non Operating Income over 5 years is $7.1 million, with a median of $735000.0 recorded in 2020.
  • Peak YoY movement for Non Operating Income: plummeted 27076.56% in 2022, then surged 5347.35% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $11.3 million in 2020, then plummeted by 1148.82% to -$118.1 million in 2021, then soared by 104.68% to $5.5 million in 2022, then soared by 5347.35% to $301.1 million in 2023, then tumbled by 96.66% to $10.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $10.1 million in Q4 2024, $11.8 million in Q3 2024, and $14.3 million in Q2 2024.